Alx oncology reports second quarter 2021 financial results and provides clinical development and operational highlights

Burlingame, calif., aug. 12, 2021 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today reported financial results for the second quarter ended june 30, 2021 and provided clinical development and operational highlights.
ALXO Ratings Summary
ALXO Quant Ranking